Falk Symposium 188

Inflammatory Bowel Diseases: Microbiota versus the Barrier

June 7 – 8, 2013
Kultur- & Kongresszentrum
Liederhalle Stuttgart
Germany

Program
Preface ........................................... 4
Scientific Program. ................................. 6
Posters ............................................. 10
List of Speakers, Moderators and Scientific Organizers ...................... 15
Information ....................................... 19
City Map of Stuttgart .............................. 21

11 credit hours (CME) have been awarded for the Falk Symposium 188 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

Dear Colleagues,

Inflammatory bowel diseases (IBD) are still enigmatic. Current concepts in Crohn’s disease underline the importance of innate immune factors including cellular receptors for bacterial components (like NOD receptors), autophagy and antimicrobial peptides including defensins. Thus, the epithelial layer including Paneth and absorptive cells enters central stage. In ulcerative colitis the mucus produced by goblet cells is apparently altered, suggesting that in both diseases the defective mucosal barrier allows bacterial invasion. This slow but uncontrolled mucosal infection is currently conceived as the primary trigger of these diseases.

In addition, alterations of the microbial flora have been observed but may be secondary to changes in host defence. Although the role of the adaptive immune system including T and B cells may have been overestimated, the proinflammatory action of immune and phagocytic cells has been a rewarding target for so called biological therapies. Since none of the current therapies, with the possible exception of probiotics, is targeting the likely primary barrier disease event, current concepts of pathophysiology as opposed to treatment dichotomize. It is likely that this “schizophrenia” is one of the reasons for suboptimal results in many patients.

This two day Falk Symposium in Stuttgart covers this conundrum extensively. The first day focuses on the interactions of gut microbiota with the mucosa in IBD whereas the second day covers different treatment strategies in guidelines from various countries, adverse events (often neglected) and, as one of the highlights, novel approaches to reconcile disease mechanisms and treatment.

We are looking forward to novel insights provided by an excellent faculty and to a great interactive discussion with all participants.

E. F. Stange       A. Dignass       K. Fellermann       K. Herrlinger
Inflammatory Bowel Diseases: Microbiota versus the Barrier

Kultur- & Kongresszentrum
Liederhalle Stuttgart
Germany

Registration:
Thursday, June 6, 2013
16.00 – 21.00 h
at the congress office

Scientific Organization:
E. F. Stange, Stuttgart (Germany)
A. Dignass, Frankfurt (Germany)
K. Fellermann, Lübeck (Germany)
K. Herrlinger, Hamburg (Germany)

Congress Venue:
Kultur- & Kongresszentrum Liederhalle
Berliner Platz 1-3
70174 Stuttgart
Germany

Information:
Prof. Dr. Eduard F. Stange
Innere Medizin I
Robert-Bosch-Krankenhaus
Auerbachstr. 110
70376 Stuttgart
Germany
Telephone: +49 (0)711/8101-3406
Telefax: +49 (0)711/8101-3793
E-Mail: eduard.stange@rbk.de

Official Language:
English.
Simultaneous translation into German.

Posters:
For details see page 10.
Friday, June 7, 2013

8.20 Welcome and Opening

Session I
The gut microbiota and the mucosa in IBD
Chair: C. L. Bevins, Davis; E. F. Stange, Stuttgart

8.30 Keynote lecture
History and philosophy of IBD
G. Rogler, Zurich

8.50 State-of-the-Art lecture
An overview of gut microbiota: Human gut microbiota and its dysfunctions
P. Lepage, Jouy-en-Josas

9.10 The mucosal flora
N. Barnich, Clermont-Ferrand

9.30 Diet and the intestinal microbiota in IBD
D. Haller, Freising

9.50 The host and the flora
S. Nuding, Stuttgart

10.10 Watching the flora in IBD mucosa
R. Kiesslich, Mainz

10.30 Coffee break with poster session

Session II
The gut barrier in IBD: The first line of defence
Chair: A. Dignass, Frankfurt; G. Rogler, Zurich

10.50 State-of-the-Art lecture
Intestinal stem cells
D. E. Stange, Dresden

11.10 Nets and harpoons: Innate immune functions of α-defensins in the small intestine
C. L. Bevins, Davis

11.30 Mucus and the goblet cells
G. C. Hansson, Gothenburg

11.50 Defective antibacterial barrier in IBD
J. Wehkamp, Stuttgart

12.10 Permeability and tight junctions in IBD
J. D. Söderholm, Linköping

12.30 Lunch break with poster session
Friday, June 7, 2013

Session III
The gut barrier in IBD: The second line of defence

Chair: K. Herrlinger, Hamburg; J. Schölmerich, Frankfurt

14.00 State-of-the-Art lecture
An overview of innate and adaptive cellular immunity in IBD
M. F. Neurath, Erlangen

14.20 What is wrong with granulocytes in IBD?
A. P. Levine, London

14.40 Local control of dendritic cell and macrophage heterogeneity in intestinal homeostasis and inflammation
A. Mowat, Glasgow

15.00 What is wrong with T- and B-lymphocytes?
H. Tilg, Innsbruck

15.20 Coffee break with poster session

Session IV
Diagnostics and prognostics in IBD

Chair: A. Stallmach, Jena; H. Tilg, Innsbruck

15.40 Antimicrobial antibodies
I. Dotan, Tel Aviv

16.00 Fecal neutrophil – derived biomarkers calprotectin and lactoferrin
T. Sipponen, Helsinki

16.20 Imaging update
H. Herfarth, Chapel Hill

16.40 Endoscopy as prognostic marker
P. Marteau, Paris

17.00 End of afternoon session
Saturday, June 8, 2013

Session V
Differences between treatment guidelines in IBD

Chair: M. F. Neurath, Erlangen; M. Zeitz, Berlin

9.00 European Crohn’s and Colitis Organisation

9.20 Germany

9.40 Great Britain

10.00 USA

10.20 Japan

10.40 Coffee break with poster session

Session VI
Adverse events

Chair: J.-F. Colombel, New York; S. Schreiber, Kiel

11.00 Aminosalicylates and corticosteroids

11.20 Immunosuppressants

11.40 Anti-TNF

12.00 Presentation of Poster Prizes

12.15 Lunch break with poster session
Saturday, June 8, 2013

Session VII
Treating microbiota and/or the barrier

Chair: K. Fellermann, Lübeck; S. B. Hanauer, Chicago

13.20 State-of-the-Art lecture
New treatments for IBD
S. Schreiber, Kiel

13.40 Antibiotics
C. Prantera, Rome

14.00 Probiotics
W. Kruis, Cologne

14.20 The lecithin story: Mucosal protection by phosphatidylcholine
W. Stremmel, Heidelberg

14.40 Trichuris suis in IBD
J. Schölmerich, Frankfurt

15.00 Coffee break with poster session

15.20 State-of-the-Art lecture
Stem cell therapy in IBD?
M. Watanabe, Tokyo

15.40 Concluding remarks
A. Dignass, Frankfurt

16.00 End of meeting
Poster Session

Posters will be exhibited on June 7 - 8, 2013, in the Kultur- & Kongresszentrum Liederhalle Stuttgart. The authors will be in attendance during coffee and lunch breaks on both days.

1. Pre-treatment with non-absorbable glucids and bovine glycomacropeptide ameliorates 5-fluorouracil-induced intestinal mucositis in rats
   A. Anzola, E. Guadix, A. Zarzuelo, F. Sánchez de Medina, O. Martínez-Augustin, R. González (Granada, ES)

2. Alternative technical approach to quantify bacterial uptake by intestinal epithelial cells
   C.J. Aranda, B. Ocón, A. Zarzuelo, M.D. Súarez, O. Martínez-Augustin, F. Sánchez de Medina (Granada, ES)

3. Predicting mucosal healing in Crohn’s disease using practical clinical indices with regard to the location of active disease

4. Elafin is upregulated by E. coli Nissle 1917 flagellin via TLR5 and NF-kappaB
   S. Becker, T.A. Ölschläger, J. Wehkamp, E.F. Stange, M. Gersemann (Stuttgart, DE)

5. Crohn’s disease masked by median arcuate ligament syndrome

6. Induction of dextran sulfate sodium colitis in germ-free conditions

7. Two cases of newly developed ulcerative colitis following clinical and endoscopical remission of acute bacterial colitis

8. Regulation of α-defensin expression by inflammatory processes and bacteria
   L. Courth, M.J. Ostaff, E.F. Stange, J. Wehkamp (Stuttgart, DE)

9. The protective effect of Echinacea spp. (Echinacea angustifolia and Echinacea purpurea) in rat colitis model induced by acetic acid
10. Genetic susceptibility to violations of mucosal barrier in ulcerative colitis and Crohn’s disease
   A.E. Dorofeyev, I.V. Vasilenko, O.A. Rassokhina (Donetsk, UA)

11. Central modulatory role of IL-9 in inflammatory bowel disease influencing barrier function
   K. Gerlach, H.-A. Lehr, A. McKenzie, M.F. Neurath, B. Weigmann (Erlangen, DE; Lausanne, CH; Cambridge, GB)

12. Increased intestinal permeability in patients with ulcerative colitis: Is there a relationship with the disease characteristics
   V. Gerova, D. Svinarov, S. Stoynov (Sofia, BG)

13. Inflammatory bowel disease in the elderly: Later is better than earlier
   A. Giannakopoulos, N.I. Mathou, K.D. Paraskeva, J.A. Karagiannis (Athens, GR)

14. Case report of intestinal amebiasis complicated by severe bacterial sepsis
   L. Goliadze, M. Kanashvili, T. Tkhilaishvili, M. Makhviladze, N. Chincharadze (Tbilisi, GE)

15. Can you similar to endoscopic and clinical presentation with Crohn’s diseases chronic mesenteric ischemia?
   F. Günes, E. Akbal, M. Asik (Canakkale, TR)

16. The first line of defense: Caspase-8 has a host-protective function through permission of controlled shedding
   C. Günther, B. Buchen, G. He, H. Neumann, M.F. Neurath, C. Becker (Erlangen, DE)

17. The value of neutrophils morphology in predicting infectious episodes in IBD patients
   G. Iliescu, V. Biciusca, L. Rosu, A. Bold (Craiova, RO)

18. Diagnostic pitfalls of dermatological lesions in IBD patients
   G. Iliescu, M. Jifcu, V. Biciusca, A. Bold (Craiova, RO)

19. Disturbance of colon microflora in patients with irritated bowel syndrome
   J. Ismailova (Tashkent, UZ)

20. Possible uses of essential phospholipids in patients with inflammatory bowel disease
   D. Janelidze, N.V. Kharchenko, I. Lopukh (Kiev, UA)

21. The gene expression of CXCL16, a chemokine and a scavenger receptor, is increased in the colonic biopsies of children with ulcerative colitis
   M. Kalliomäki, M. Ashorn, T. Ruuska (Turku, Lappeenranta, Tampere, Fl)
22. The case of colitis caused by Clostridium difficile and not associated with antibiotic therapy
M. Kanashvili, N. Rukhadze, M. Makhviladze, L. Kajaia, L. Goliadze, T. Tkhilaishvili, T. Rurua, T. Akhvlediani (Tbilisi, GE)

23. The role of premorbid gastrointestinal conditions in the development of amebiasis
M. Kanashvili, N. Rukhadze, M. Makhviladze, L. Kajaia, L. Goliadze, T. Tkhilaishvili, T. Rurua, T. Akhvlediani (Tbilisi, GE)

24. Increased transepithelial transport of E. coli LF82 via the follicle-associated epithelium in ileal Crohn’s disease
A.V. Keita, O. Yakymenko, B. Chassaing, A. Darfeuille-Michaud, J.D. Söderholm (Linköping, SE; Clermont-Ferrand, FR)

25. The impact of iron deficiency without anemia and iron deficiency anemia on quality of life in inflammatory bowel disease: A comparative retrospective study

26. Analysis of intestinal microbiome of a recovered Clostridium difficile patient after stool transplant
M. Kube, J. Klumpp, J. Hecht, F. Bröcker, M. Hombach, G. Rogler, R. Speck, K. Mölling (Berlin, Potsdam, DE; Zürich, CH)

27. Characterization of the antimicrobial activity of high-mobility group box 2
R. Küchler, B.O. Schröder, S. Nuding, E.F. Stange, J. Wehkamp (Stuttgart, DE)

28. Bile acids regulate innate barrier functions of colonic epithelial cells
N.K. Lajczak, M.S. Mroz, V. Saint-Criq, S.J. Keely (Dublin, IE)

29. Reconstructed oral epithelium as model to study probiotic – host – pathogen interactions
D. Mailänder-Sánchez, J. Wagener, C. Braunsdorf, J. Wehkamp, M. Schaller (Stuttgart, Tübingen, DE; Aberdeen, GB)

30. C-Jun N-terminal kinases improve gastrointestinal barrier function
A.D. Mandic, E. Bennek, S. Sackett, F. Javier Cubero, C. Trautwein, G. Sellge (Aachen, DE)

31. Tissue nonspecific alkaline phosphatase heterozygous mice are protected against DSS experimental colitis due to an increase of T cell response
32. The flavonoid quercetin fails to attenuate experimental ileitis despite epithelium-dependent downregulation of IFN-γ production
   C. Mascaraque, M.J. Monte, A. Anzola, M. González, J.J. G Marin, M.D. Suarez, A. Zarzuelo, O. Martínez-Augustin, F. Sánchez de Medina (Granada, ES)

33. Expression of mRNA-specific cytokine profiles in the colonic mucosa of patients with IBD
   T. Mladenova, I. Karakolev, Z. Spassova, E. Ivanova-Todorova, D. Kyurkchiev, I. Altankova, S. Stanilova (Sofia, Stara Zagora, BG)

34. Relation between a single nucleotide polymorphism in MORC4, NOD2 variants and outcome after allogeneic stem cell transplantation for hematological malignancies

35. Probiotics isolated from Funazushi modulates NK-1R expression in colonic epithelial cells in vitro and attenuated DSS-induced colitis

36. Changes in the colonic transportome evoked by the total or subtotal absence of microbiota in mice and modulation by bacterial antigens
   M. Ortega-González, C.J. Aranda, A. Zarzuelo, M.D. Súarez, F. Sánchez de Medina, O. Martínez-Augustin (Granada, ES)

37. Plasmoblastic lymphoma presenting as a paravertebral mass in a patient with Crohn’s disease after immunosuppressive therapy
   N. Osmanoglu, I. Ovul, F. Hekimgil (Izmir, TR)

38. WNT pathway ligands, Paneth cells and small intestinal Crohn’s disease
   M.J. Ostaff, Z. Teltschik, L. Courth, E.F. Stange, J. Wehkamp (Stuttgart, DE)

39. Crohn’s disease with isolated small bowel involvement
   E. Panteleeva, R. Shentova, P. Yaneva, M. Baycheva, C. Zhelev (Sofia, BG)

40. Fluctuations in butyrate-producing bacteria correlate with the production of pro-inflammatory cytokines in different stages of ulcerative colitis
   J. Paul, R. Kumari, R. Verma (New Delhi, IN)

41. Antimicrobial peptides defensins as a link between chronical inflammation and ductal adenocarcinoma of the pancreas
   T. Pausch, S. Schneider, K. Felix, N. Giese, M.W. Büchler, J. Werner, W. Hartwig (Heidelberg, DE)
42. The treatment with aminosalicylates – Safety and adverse effects
   O. Petrescu, A. Pop (Sibiu, RO)

43. A net is not enough: Reducing environment modulates antibiotic activity of
   human alpha-defensin 6
   B.O. Schröder, J. Berger, R. Küchler, M. Schaller, E.F. Stange, J. Wehkamp
   (Stuttgart, Tübingen, DE)

44. Fecal calprotectin as non-invasive marker of intestinal inflammation in children
   R. Shentova, E. Panteleeva, P. Yaneva, M. Baycheva, C. Zhelev (Sofia, BG)

45. Small intestinal bacterial overgrowth in children with gastrointestinal symptoms
   K. Siniewicz-Luzenczyk, A. Krakowska, A. Slemp, M. Ludzik, K. Zeman,
   L. Bak-Romaniszyn (Łódz, PL)

46. Stat3 differentially regulates intestinal epithelial cell antimicrobial peptide
   production in vivo
   S.J. Wirtz, U. Billmeier, N. Wittkopf, R. Lakra, M.F. Neurath (Erlangen, DE)

47. Transepithelial transport of E. coli LF82 in an in vitro follicle-associated epithelium
   model
   O. Yakymenko, A.V. Keita, B. Chassaing, B.O. Schröder, J. Wehkamp,
   A. Darfeuille-Michaud, J.D. Söderholm (Linköping, SE; Clermont-Ferrand, FR;
   Stuttgart, DE)

48. Ascites and proteinuria caused by systemic amyloidosis in a patient with Crohn’s
   disease
   K. Yildiz, O. Kocaman, H. Sentürk, A. Danalioglu, K. Turkdogan, B. Baysal,
   A.T. Ince (Fatih-Istanbul, TR)
List of Speakers, Moderators and Scientific Organizers

Dr. Nicolas Barnich
Université d’Auvergne
CBRV
26 Place H. Dunant
63000 Clermont-Ferrand
France
nicolas.barnich@udamail.fr

Charles L. Bevins, M.D.
Professor of Medicine
University of California
School of Medicine
Med. Microbiology & Immunology
One Shields Ave., Tupper Hall
Davis CA 95616
USA
clbevins@ucdavis.edu

Prof. Dr. Jean-Frederic Colombel
Henry D. Janowitz Division
of Gastroenterology
One Gustave L. Levy Place
Box 1069
New York NY 10029
USA
jean-frederic.colombel@mssm.edu

Prof. Dr. Axel Dignass
Medizinische Klinik I
AGAPLESION
Markus Krankenhaus
Wilhelm-Epstein-Str. 4
60431 Frankfurt
Germany
axel.dignass@fdk.info

Dr. Iris Dotan
Tel Aviv Medical Center
Ichilov Hospital
Department of Gastroenterology
6, Weizman Street
64239 Tel Aviv
Israel
irisd@tasmc.health.gov.il

Prof. Dr. Klaus Fellermann
Medizinische Klinik I
Universitätsklinikum Schleswig-Holstein, Campus Lübeck
Ratzeburger Allee 160
23538 Lübeck
Germany
klaus.fellermann@uk-sh.de

Prof. Dr. Dirk Haller
Lehrstuhl für Biofunktionalität der Lebensmittel
Wissenschaftszentrum Weihenstephan
Technische Universität München
Gregor-Mendel-Str. 2
85350 Freising
Germany
haller@wzw.tum.de

Stephen B. Hanauer, M.D.
Professor of Medicine
University of Chicago
Department of Medicine
Gastroenterology Section
5841 S. Maryland Ave.
Chicago IL 60637-1463
USA
shanauer@medicinebsd.uchicago.edu

Prof. Dr. Gunnar C. Hansson
University of Göteborg
Mucin Biology Group
Dept. of Medical Biochemistry
405 30 Göteborg
Sweden
gunnar.hansson@medkem.gu.se

Hans Herfarth, M.D.
Associate Professor of Medicine
University of North Carolina
Gastroenterology & Hepatology
4151 Bioinformatics Bldg.
130 Mason Farm Road
Chapel Hill NC 27599-7080
USA
hherf@med.unc.edu
Prof. Dr. Klaus Herrlinger  
Innere Medizin  
Aklepios Klinik Nord  
Betriebsteil Heidelberg  
Tangstedter Landstr. 400  
22417 Hamburg  
Germany  
k.herrlinger@asklepios.com

Prof. Dr. Toshifumi Hibi  
Keio University  
School of Medicine  
Department of Internal Medicine  
35, Shinano-machi  
Shinjuku-ku  
Tokyo 160-8582  
Japan  
thibi@z5.keio.jp

Prof. Dr. Ralf Kiesslich  
Innere Medizin I  
Universitätsmedizin der  
Johannes Gutenberg-Universität  
Langenbeckstr. 1  
55131 Mainz  
Germany  
kiesslich@uni-mainz.de

Prof. Dr. Wolfgang Kruis  
Innere Medizin  
Evang. Krankenhaus Kalk  
Buchforstr. 2  
51103 Köln  
Germany  
kruis@evkk.de

Prof. Dr. Gerd A. Kullak-Ublick  
Universitätsspital Zürich  
Klinik für Klinische Pharmakologie  
und Toxikologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
gerd.kullak@usz.ch

Dr. Patricia Lepage  
INRA Domaine de Vilvert  
Département  
d'Hépato-Gastroentérologie  
78352 Jouy-en-Josas  
France  
patricia.lepage@jouy.inra.fr

Dr. Adam P. Levine  
Rayne Institute  
Centre for Molecular Medicine  
Division of Medicine  
University College London  
5 University Street  
London WC1E 6JF  
Great Britain  
a.levine@ulc.ac.uk

Prof. Dr. Philippe Marteau  
Lariboisiere Hôpital  
Service d’Hepato-Gastroenterologie  
2, rue Ambroise Paré  
75010 Paris  
France  
philippe.marteau@lrb.aphp.fr

Prof. Dr. Allan Mowat  
University of Glasgow  
Western Infirmary  
Department of Immunology  
Glasgow G11 6NT  
Great Britain  
allan.mowat@glasgow.ac.uk

Dr. Craig Mowat  
University of Dundee  
Ninewells Hospital  
Department of Gastroenterology  
Dundee DD1 9SY  
Great Britain  
craig.mowat@nhs.net

Prof. Dr. Markus F. Neurath  
Medizinische Klinik I  
Universitätsklinikum  
Erlangen-Nürnberg  
Ulmenweg 18  
91054 Erlangen  
Germany  
markus.neurath@uk-erlangen.de
Dr. Sabine Nuding  
Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie  
Auberbachstr. 112  
70376 Stuttgart  
Germany  
sabine.nuding@ikp-stuttgart.de

Dr. Taina Sipponen  
Helsinki University Central Hospital  
Department of Medicine  
Division of Gastroenterology  
00029 Helsinki  
Finland  
taina.sipponen@kolumbus.fi

Prof. Dr. Cosimo Prantera  
Azienda Ospedaliera  
S. Camilo Forlanini  
Via Portuense, 292  
00149 Rom  
Italy  
prantera@tin.it

Prof. Dr. Dr. Gerhard Rogler  
Universitätsspital Zürich  
Klinik für Gastroenterologie & Hepatologie  
Rämistr. 100  
8091 Zürich  
Switzerland  
gerhard.rogler@usz.ch

Prof. Dr. Andreas Stallmach  
Gastroenterologie/Hepatologie  
Klinikum der  
Friedrich-Schiller-Universität Jena  
Erlanger Allee 101  
07747 Jena  
Germany  
andreas.stallmach@med.uni-jena.de

Prof. Dr. Eduard F. Stange  
Innere Medizin I  
Robert-Bosch-Krankenhaus  
Auerbachstr. 110  
70376 Stuttgart  
Germany  
eduard.stange@rbk.de

Prof. Dr. Wolfgang Stremmel  
Innere Medizin IV  
Universitätsklinikum Heidelberg  
Im Neuenheimer Feld 410  
69120 Heidelberg  
Germany  
wolfgang_stremmel@med.uni-heidelberg.de
Prof. Dr. Herbert Tilg
Universitätsklinik Innsbruck
Innere Medizin I
Anichstr. 35
6020 Innsbruck
Austria
herbert.tilg@i-med.ac.at

PD Dr. Jan Wehkamp
Innere Medizin I
Robert-Bosch-Krankenhaus
Auerbachstr. 110
70376 Stuttgart
Germany
jan.wehkamp@ikp-stuttgart.de

Prof. Dr. Mamoru Watanabe
Tokyo Medical & Dental University
School of Medicine
Department of Gastroenterology
1-5-45, Yushima, Bunkyo-ku
Tokyo 113-8519
Japan
mamoru.gast@tmd.ac.jp

Prof. Dr. Martin Zeitz
Gastroenterologie
Charité Universitätsmedizin
Campus Benjamin Franklin (CBF)
Hindenburgdamm 30
12203 Berlin
Germany
martin.zeitz@charite.de
Congress Office
During Falk Symposium 188
Telephone: +49 (0)175/7795327
Kultur- & Kongresszentrum Liederhalle
Berliner Platz 1-3
70174 Stuttgart
Germany

Opening Hours:
Thursday, June 6, 2013 16.00 – 21.00 h
Friday, June 7, 2013 7.30 – 17.30 h
Saturday, June 8, 2013 8.30 – 16.00 h

Congress Fees
Scientific program of the Falk Symposium 188 € 200,–
Students and residents € 100,–

* * * OR * * *

Day ticket € 120,–
Students and residents € 60,–

Employees of pharmaceutical companies and their guests
Falk Symposium 188 € 600,-

The congress fees include:
- Welcome Evening
- Refreshments during coffee breaks
- Lunch on June 7 and 8, 2013
- A copy of the abstract volume
Admission to Scientific Events
For admission to scientific events your name badge should be clearly visible.

Congress Report
The official congress report of the Falk Symposium 188 “Inflammatory Bowel Diseases: Microbiota versus the Barrier” will be published in English in the second half of 2013 by Karger, Switzerland. Orders for this book at a reduced subscription price of € 35,- can be placed at the Congress Office during the congress in Stuttgart.

Airport
International Airport Stuttgart
Directions to Kultur- & Kongresszentrum Liederhalle

**By car:**
Coming from Munich on the A8 (exit Degerloch, take the B27),
coming from Karlsruhe on the A8 (exit Vaihingen, take the B14),
coming from Heilbronn on the A81 (exit Zuffenhausen, take the B10 and B27),
please follow the “Kultur- und Kongresszentrum Liederhalle” signs.

**By train:**
Stuttgart main station with IC/ICE connections.
Take the tram, line 9 or 14. Station Berliner Platz.

**By plane:**
The international airport Leinfelden-Echterdingen is 15 km distance from the hotel.
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue
in the interest of therapeutic progress
Falk Symposia and Workshops over 250 with almost 130,000 international participants since 1967
Continuing medical education seminars over 15,500, attended by more than 1.2 million physicians and patients in Germany alone
Comprehensive literature service for healthcare professionals and patients with more than 200 publications

www.falkfoundation.org
www.drfalkpharma.com
Inflammatory Bowel Diseases: Microbiota versus the Barrier

June 7 – 8, 2013
Kultur- & Kongresszentrum
Liederhalle Stuttgart
Germany

Program